Orchestra BioMed Launches Underwritten Stock Offering to Fund BACKBEAT and Virtue Trials
OBIO sits 61% above its 52-week low of $3.46.
Summary
Orchestra BioMed launched an unpriced underwritten common stock offering, with proceeds earmarked for its BACKBEAT and Virtue clinical programs and management projecting funding through 2028. Terms, including share count and price, are still blank pending pricing.
Key Events · Financing and Capital Events · OBIO
-
Underwritten Follow-On Launched, Terms Unpriced
A preliminary prospectus supplement dated November 5, 2026 covers an offering of common stock; the number of shares, public offering price and net proceeds are all left blank pending pricing. Piper Sandler, TD Cowen and BTIG are joint bookrunners.
-
Greenshoe and Lock-Up Terms
Underwriters get a 30-day option to buy up to an unspecified number of additional shares. The company and its directors and executive officers agreed to a 60-day lock-up, and the company will reimburse underwriter expenses up to $200,000.
-
Runway Extended to 2028 on Combined Cash
Management states net proceeds plus existing cash and marketable securities fund operating expenses and capital expenditures through 2028. Preliminary unaudited cash, cash equivalents and marketable securities were approximately $102 million as of September 30, 2026.
-
Use of Proceeds Tied to Two Pivotal Programs
Proceeds fund the AVIM Therapy program and BACKBEAT Trial and the Virtue SAB program and Virtue Trial, plus research and development of other candidates, with the remainder for working capital.
Analysis · OBIO · Industrial Applications And Services
Orchestra is returning to equity markets with a marketed follow-on, roughly three months after reporting a $23.8M quarterly loss on $88K of revenue. Because the deal is still unpriced — share count, public offering price and net proceeds are blank in this preliminary supplement — the size of the dilution is not yet knowable. The structure, however, is a firm-commitment underwriting led by Piper Sandler, TD Cowen and BTIG with a 30-day greenshoe. Management says the money, plus existing cash, funds operations through 2028, covering the BACKBEAT primary endpoint readout targeted for a Q2 2027 conference and the Virtue Trial enrollment expected to finish by end-2027. That runway claim is the main thing investors get for the dilution. Against it: 61,453,382 shares were outstanding as of November 4, 2026, and the cap table already carries heavy overhang — about 3.9M pre-funded warrants at $0.0001, 2.0M Ligand warrants at $3.67, plus roughly 12.4M options and RSUs — so per-share value is squeezed from several directions at once. The $86.2M still available under the existing TD Cowen sales agreement (dated August 12, 2024) remains a separate, ongoing drip that this deal does not retire.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OBIO was trading at $5.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $337.8M. The 52-week trading range was $3.46 to $6.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.